Sign in
CompletedNo phase

Transcutaneous CO₂ Therapy in Recurrent Hard-to-Heal Diabetic Foot Ulcers

Key facts

Who runs it
University Medical Centre Ljubljana
Where
Slovenia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
30 people enrolled
Started
1 Sept 2024
Ended
30 Aug 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • transcutaneous application of gaseous CO2 on lower part of the body
Record updated
24 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • diabetes mellitus type 1 or 2
  • recurrent hard to heal DFU

Who cannot take part

  • malignant diseases
  • infected ulcer at baseline
  • KOPD stage IV
  • CKD stage IV
  • pregnancy
  • inability to comply with visits

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Recurrent and hard-to-heal diabetic foot ulcers (DFUs) represent a clinically challenging subgroup with delayed closure and frequent non-response to standard of care (SOC). Impaired local perfusion and superficial tissue hypoxia, commonly attributed to microcirculatory dysfunction, are proposed contributors to impaired wound-bed progression and prolonged healing trajectories in diabetes. Transcutaneous gaseous carbon dioxide (CO₂) therapy is a non-invasive adjunct intervention with a mechanistic rationale to modulate local microcirculation and tissue oxygenation; however, controlled clinical evidence in recurrent, hard-to-heal DFUs remains limited. This prospective, randomized, controlled, open-label, parallel-group clinical investigation compares transcutaneous CO₂ therapy plus SOC versus SOC alone over 4 weeks. The primary objective is to determine whether the proportion of completely healed DFUs at Week 4 differs between groups under a predefined healing confirmation procedure. Key secondary objectives include quantifying changes in superficial tissue oxygenation (StO₂) using hyperspectral imaging and assessing pain intensity (NPRS). Supportive outcomes include ulcer area reduction metrics and wound-bed appearance in unhealed.

The 2 groups in the trial

  • Standard of care + CO2 therapyTreatment being tested

    Standard of care (3 times weekly) + transcutaneous gaseous CO2 therapy 20 times (every weekday for 50 minutes)

    Treatment: transcutaneous application of gaseous CO2 on lower part of the body

  • Standard of careNo study treatment, for comparison

    Standard of care (3 times weekly)

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
24 February 2026